TBC AstraZeneca Pty Ltd
Product name
TBC
Sponsor
Accepted date
Jul-2026
Active ingredients
tozorakimab
Summary of proposed indication
Tozorakimab is proposed as an additional long-term treatment for adults with chronic obstructive pulmonary disease, or COPD. COPD is a lung disease characterised by persistent respiratory symptoms and narrowing of the airways, which can cause difficulty in breathing.
Application type
A (new medicine)
Publication date
Jul-2026